The Role of Histone Acetylation in Mesenchymal Stem Cell Differentiation

Sujeong Jang†, Jinsu Hwang†, and Han-Seong Jeong*

Department of Physiology, Chonnam National University Medical School, Hwasun, Korea

The mechanism and action concerning epigenetic modifications, especially that of histone modifications, are not fully understood. However, it is clear that histone modifications play an essential role in several biological processes that are involved in cell proliferation and differentiation. In this article, we focused on how histone acetylation may result in differentiation into mesenchymal stem cells as well as histone acetylation function. Moreover, histone acetylation followed by the action of histone deacetylase inhibitors, which can result in the differentiation of stem cells into other types of cells such as adipocytes, chondrocytes, osteocytes, neurons, and other lineages, were also reviewed.

Key Words: Mesenchymal Stem Cell; Cell Differentiation; Histone Acetylation; Epigenesis, Genetic

INTRODUCTION

Epigenetic modifications are one of the primary mechanisms causing early programming of cell proliferation, differentiation, death, and disease. Mesenchymal stem cells (MSCs) differentiation through epigenetic manipulation into specialized cells has the potential to advance the field of regenerative medicine through several tissue engineering processes. Several studies support the involvement of epigenetic mechanisms through gene expression control, stem cell self-renewal and lineage fate determination. During differentiation into a particular lineage, the specific genes of this lineage undergo active transcription. Consequently, the genes responsible for self-renewal and pluripotency are repressed. This on-off mechanism is associated with posttranslational modifications, especially histone acetylation/methylation and promoter DNA methylation. These epigenetic modifications are critical for regulating gene expression, and several researchers have shifted their focus to one or the other.

HISTONE MODIFICATION

Chromatin is an instructive DNA scaffold that can regulate several functional features of DNA and plays a vital role in histone modification. Histone modifications exert their function through specific enzymes, and different enzymes modify different sites (based on specificity at the enzyme’s active site) or have different functions. For example, Gcn5 and p300-CBP acetylate H3K9/H3K27 sites, Ezh2 methylates H3K27 sites, and Suv39h1 plays a role in H3K9 methylation. The enzyme, DNA methyltransferase (DNMT)-1, is responsible for maintenance of DNA methylation, and DNMT3a/b is responsible for de novo DNA methylation. However, it remains unclear which specific enzymes are involved in MSC differentiation and how these enzymes interact with one another.

1. Histone acetylation and methylation

Histone acetylation was first reported by Allfrey et al. in 1964, who suggested that histones are post-translationally modified. The acetylation of lysine residues is highly dynamic and regulated by the opposing action of two families of enzymes, i.e., histone acetyltransferases (HATs) and histone deacetylases (HDACs).

There are two general categories of HATs in humans: Type A HATs are nuclear and acetylate nucleosomal histones and other chromatin-associated proteins. Examples of type A HATs are the GCN5-related N-acetyltransferase family, Moz-Ybf2/Sas3-Sas2-Tip60 family, and p300/CREB-
binding protein (CBP/CREBBP) family. Typically, each of these enzymes modifies multiple sites within the histone N-terminal tails. Type B HATs are located in the cytoplasm and acetylate the newly synthesized histone H4 at K5 and K12, where this pattern of acetylation is important for deposition of the histones. Additionally, type B HATs share sequence homology with scHat1 and have no direct impact on transcription.

HDAC inhibitors are a class of compounds that increase acetylation of lysine residues on histone proteins as well as other, nonhistone, proteins by inhibiting the activity of HDAC enzymes. HDACs contain the presence of cellular and target proteins involved in cancer progression, apoptosis, cell cycle control, angiogenesis, and cell invasion. This is corroborated by HDAC inhibitors that show involvement in the activation of the apoptotic pathway, cell cycle arrest, and apoptotic induction via the extrinsic (death receptor) pathway or the intrinsic (mitochondrial) pathway, both of which lead to caspase activation and cell death induction. HDAC inhibitors can induce cell cycle arrest at G1/S or G2/M transcription, resulting in differentiation and/or apoptosis.

Histone methyltransferase (HMT) are histone-modifying enzymes involved in inhibiting gene expression and heterochromatin formation. Previous studies have reported that HMTs interact with HATs at the H3K9 site and affect histone methylation levels in this region. It has been indicated that histone methylation is a vital part of epigenetic modification interactions. DNA methylation is best known for its role in gene silencing for it can alter gene expression without changing a given gene’s base sequence. Among epigenetic mechanisms, post-translational histone modification plays a central role and are brought about by a series of ‘writing’ and ‘erasing’ events by histone-modifying enzymes.

2. Histone modifying enzymes; writers, erasers, and readers

A wide range of post-translational modifications (PTMs) primarily targeting amino acids within the N-terminal tails of histone proteins occurs, including phosphorylation, acetylation, methylation, ubiquitination, SUMOylations, and Gcn5acetylation. Governance of chromatin structure through histone PTMs has emerged as an essential driver of transcriptional responses in numerous cells. Like histone writers, erasers, and readers, the protein machinery that adds, removes, or recognizes PTMs has become revolutionary in our understanding of physiological responses. In this review, we summarize how histone acetylation or methylation is carried out by writers and erasers, their acetylation Bromo. These domains are located within the chromatin modifying proteins and respond to histone acetylation or methylation. Histone methyltransferase (HMT) are histone-modifying enzymes involved in inhibiting gene expression and heterochromatin formation. Previous studies have reported that HMTs interact with HATs at the H3K9 site and affect histone methylation levels in this region. It has been indicated that histone methylation is a vital part of epigenetic modification interactions. DNA methylation is best known for its role in gene silencing for it can alter gene expression without changing a given gene’s base sequence. Among epigenetic mechanisms, post-translational histone modification plays a central role and are brought about by a series of ‘writing’ and ‘erasing’ events by histone-modifying enzymes.

1) Writers

Writers are enzymes that add PTMs to histones and are divided into classes based on the specific PTM, HATs, and HMTs. In humans, there are three major families of HATs: the Gcn5-related N-acetyltransferase family (GNAT), the MYST family (MOZ, YbF2, Sas2, TIP60), and the orphan family (DBP/EP300 and nuclear receptors), whose structure and mechanism of action are elaborated by Marmorstein and Zhou in a paper published in 2014. In general, HATs function as components within a diverse set of multiprotein complexes that target promoters and enhancers in order to regulate specific transcriptional responses.

In 1999, Allis's group first reported a link between histone methylation and DNA transcription, and discovered and identified specific HMTs the following year. There are several families of HMTs, such as the SET family, which has a SET domain or non-SET domain-containing methyltransferases, and SUV39, which was the first protein identified in the SET family. Modifications associated with active transcription include di- or tri-methylation of H3K4 (H3K4me2, H3K4me3) and mono-methylation of H3K9 (H3K9me1). However, di- and tri-methylation of H3K9 (H3K9me2, H3K9me3), as well as H3K27 (H3K27me2, H3K27me3), are repressive markers. Unlike histone acetylation, histone methylation can be linked to either transcriptional repression or activation depending on the context and extent of methylation.

2) Erasers

Similar to writers, erasers are enzymes that remove specific PTMs from histone substrates. Erasers are classified on HDACs and histone demethylases. Currently, 18 mammalian HDACs have been identified and categorized into four major classes: Class I: HDACs 1, 2, 3, and 8; class IIa: HDACs 4, 5, 7, and 9; class IIb: HDACs 6 and 10. The sirtuins comprise class III, and HDAC 11 comprising the sole HDAC in class IV. Identify the HDAC component molecules as well as understanding their activity is essential in for their emergence as a potential therapeutic strategy for treatment of disease, including cancer, immune disorders, and heart disease.

Histone demethylases play regulatory roles in transcription for demethylation of histones, including the Jumonji C family, JHMD1, JMJD3, and JMJD2D. Similar to HDACs, small molecular inhibitors of demethylase activity are being developed for use as potential therapeutics to modulate DNA transcription in disease.

3) Readers

Readers are dedicated protein factors that recognize either specific post-translational marks on histones or a combination of marks and histone variants to direct a particular transcriptional outcome. Just as the function of histone PTM is carried out by writers and erasers, their actions that govern DNA transcription are mediated by readers. They have domains, which have a high affinity for sites of histone methylation, chromo, Tudor, MBT, or acetylation Bromo. These domains are located within the chromatin modifying proteins and respond to histone PTMs. In addition, both the chromatin remodeler complex switching defective/sucrose non-fermenting (SWI/SNF) and the bromodomain and extra-terminal domain (BET) families are examples of readers.
The Role of Histone Acetylation in Mesenchymal Stem Cell Differentiation

**Table 1. Summary of principal writer, eraser, and reader protein for histone acetylation and methylation in mesenchymal stem cells**

| Family                               | Activity                          | Major catalytic site | Major classes          | Representative member | Classic inhibitors        |
|--------------------------------------|-----------------------------------|----------------------|------------------------|-----------------------|--------------------------|
| **Writers**                          |                                   |                      |                        |                       |                          |
| Histone acetyltransferase            | Catalyze histone acetylation      | H3K9/K14/K56, H4K5/K8/K16, H3AK5 | (1) Gcn5/PCAF         | P300/CBP, Tip60, Gcn5, ELFP3, HAT1, MYST | Acetyl-CoA derivatives, anacardic acid, curcumin |
|                                      |                                   |                      | (2) MYST              |                       |                          |
|                                      |                                   |                      | (3) p300/CBP          |                       |                          |
|                                      |                                   |                      | (4) Rtt109            |                       |                          |
| Histone methyltransferase            | Catalyze histone methylation      | H3K4/K9/K27/K35/K79, H4K20, H3R8 | (1) SUV39             | DOT1L, EZH2, SUV39H1, SUV4-20, SMYD | EPZ00477, GSK343, UNC1999 |
|                                      |                                   |                      | (2) SET1              |                       |                          |
|                                      |                                   |                      | (3) SET2              |                       |                          |
|                                      |                                   |                      | (4) RIZ               |                       |                          |
|                                      |                                   |                      | (5) PRMTs             |                       |                          |
| **Erasers**                          |                                   |                      |                        |                       |                          |
| Histone deacetylases                 | Catalyze histone deacetylation    | H3K9/K14, H4K5/K12/K8 | (1) HDACI             | HDAC1,2,3,8           | TCA, vorinostat, romidepsin |
|                                      |                                   |                      | (2) HDACII            | HDAC5,6,7,9           |                          |
|                                      |                                   |                      | (3) HDACIII           | SIRT1-6               |                          |
|                                      |                                   |                      | (4) HDACIV            | HDAC11                |                          |
| Histone demethylase                  | Catalyze histone demethylation    | H3K4/K9/K27/K36/K79, H4K20 | (1) Lysine-specific demethylases | JMJD2A, KDM5B, KDM2A | Tranylcypromine, GSJ-J1, 8-hydroxyquinolines |
|                                      |                                   |                      | (2) Jamonji domain-contain demethylase |                       |                          |
| **Readers**                          |                                   |                      |                        |                       |                          |
| Bromodomain-containing proteins      | Binding the acetylated lysine residue | H3K14, H4K5/K8/K16 | Bromodomains          | GCN5, Brdt, Rsc4      | JQ1, GSJ2801              |
| PHD-containing proteins              | Binding the methylated lysine residue, or the acetylated lysine residue | H3K4/K9/K14 | PHD domains | RAG2, BHC80, TAF3, Tandem-PHD |                          |
| Methyl-lysine-and/methyl-arginine-binding domain-containing proteins | Binding the methylated lysine residue, or the methylated arginine residue | H3J4/K9/K23/K27/K36/K79, H4K20, H1K26, H3R17, H4R3 | (1) Tudor domains | 53BP1/Crb2, HP1, PHF20L1, TTD, ZF-CW, MBT, DCD | UNC669, UNC1215 |
|                                      |                                   |                      | (2) MBT domains       |                       |                          |
|                                      |                                   |                      | (3) Chromodomains     |                       |                          |
|                                      |                                   |                      | (4) PWWP domains      |                       |                          |

**HISTONE ACETYLATION IN MESENCHYMAL STEM CELL DIFFERENTIATION**

MSCs are emerging as extremely promising therapeutic agents for tissue regeneration and disease, in part because of their multipotent properties and capacity for self-renewal. Several studies have successfully induced MSC differentiation into specialized cells through different methods. However, the molecular mechanism of differentiation remains unclear, which results in low induction efficiency and limits the clinical application of MSCs. Stem cell self-renewal and differentiation require selective action or silencing of specific transcriptional programs in response to environmental cues. This crosstalk between transcriptional factors and epigenetic modulators regulating the chromatin conformation affects stem cell differentiation following specific gene promoters. The epigenetic mechanisms governing MSC identity and fate determination are not well understood and remain an active area of investigation. Furthermore, the enhancement of stem cell differentiation ability is a challenge for type specialization, and it is possible to increase its ability of stem cells through histone modification in basic research and clinical treatment.

Differentiation requires orchestration of numerous parallel cellular responses and altered physiological states associated with the novel cell fate. These changes are induced by environmental cues, such as soluble factors or cell-to-cell connection, that is expected to transduce and translate gene expression. Cardiomyogenic differentiation following histone modification requires the coordination of transcriptomic reprogramming and nucleosome remodeling. We summarize how histone regulator act to differentiate into other cell lineages in mesenchymal stem cells (Fig. 1).

1. Cardiomyogenic differentiation

There are several studies regarding cardiomyogenic differentiation of MSCs. In 2009, Feng et al. reported that histone acetylation, not DNA methylation, might be one of the mechanisms of cardiac differentiation of rat MSCs.
They induced differentiation into cardiomyocyte with suberoylanilide hydroxamic acid (SAHA, a HDAC inhibitor) or 5-azacytidine (5-aza, a DNA methylation inhibitor) and demonstrated that SAHA effectively promoted cardiomyocyte differentiation in vitro. In addition, they focused on Gcn, which linked a known transcriptional coactivator with catalytic histone acetyltransferase activity, and determined its importance in differentiating into cardiomyocytes caused by modification of histone H3. Inhibition of HDAC1 or HDAC2 by siRNA targeting increased cardiac-specific gene expression and local enrichment of the level of histone acetylation of H3 and H4 in MSCs, further verifying that HDAC1 and HDAC2 are involved in cardiac differentiation.

FIG. 1. Role of histone acetylation in MSC differentiation. Histone acetylation is regulated by the histone acetyltransferase (HAT) and histone deacetylase (HDAC) which converts chromatin structures. A variety of histone modifying enzymes is involved in the MSC fate determination with acetylation and methylation of specific catalytic sites through their representative members.

For long-term cultivation, MSCs in early and late passage were examined for different gene expression; the osteogenic genes increased, while the stemness genes, such as Oct4 and Sox2, declined markedly. Several studies have reported that histone acetylation levels, specially histone H3 acetylation in K9 and K14 and gene promoter DNA methylation, are essential to regulate osteogenic differentiation. In addition, valproic acid (VPA), a HDAC inhibitor, promoted the level of histone H3 lysine 9 acetylation (H3K9Ac) and the expression of osteogenesis-related genes, including Runx2, Osterix, osteocalcin, osteopontin, and alkaline phosphate, and induced the regulation of Runx2 activity. Following the study by Fani et al., chromatin immunoprecipitation results showed significant changes in the H3K9Ac on regulatory regions of stemness (Nanog, Sox2, Rex1), osteogenic (Runx2, OC, Sp7), and adipogenic (PPARγ, Lpl, adiponectin) marker genes between undifferentiated and differentiated cells. In addition, adrenalone inhibited osteogenic differentiation by reducing miRNA-21 expression and enhancing RUNX2, OSX, OCN, and OPN expression in hMSCs. Recently, Su et al. reported that c-Jun signaling could help facilitate acetylation of H3K27, which has acetylation transferase p300 to RUNX2 promoter, during osteogenic differentiation.

Zhou’s group reported that the histone H3K9 acetyltransferase, PCAF has an essential role in osteogenic differentiation of MSCs and controlled BMP signaling both in vitro and in vivo, especially aged mice. In addition, the activity between histone acetylation and Wnt genes, especially, Wnt1, Wnt6, Wnt10a, and Wnt10b, increased Gcn5 methylation, are essential to regulate osteogenic differentiation. These results might represent a therapeutic target for stem cell-based regenerative medicine and the treatment of disease.

Last year, Hansen’s group revealed that the activation of the PLZF transcription factors encoded by ZBTB16 plays a role in osteogenic differentiation at the pre-osteoblast stage and is influences H3K27 acetylation and osteogenic gene expression. Furthermore, the nicotinamide N-methyltransferase (NNMT) gene is a promoter of PLZF and requires osteogenic differentiation.

3. Adipogenic differentiation

Adipogenesis is a complex physiological process with gene expression by various adipogenic factors, including, Pref-1, C/EBPβ, C/EBPδ, PPARγ, and aP2. In undifferentiated stem cells, inactive lineage-specific promoters are in an enriched combination of trimethylated H3K4m3 and H3K27m3 in the absence of H3K9m3, a heterochromatin mark. Following differentiation, adipogenic and myogenic promoters are enriched in trimethylated H3K4, K27, and K9, which is associated to the potential of activation.

The balance between osteogenesis and adipogenesis of bone marrow-derived MSCs is known to induce stem cell differentiation and is a promising therapeutic approach in disease. Several studies have suggested that DNA methylation and histone acetylation have been linked by PPARγ in regulating MSC differentiation, which allows for the accumulation of HDAC1 to downregulate the acetylation status. Therefore, the status of DNA methylation and histone acetylation might be regarded as an adipogenic potential.

Sakai’s group recently reported that H3K4/H3K9m3...
bivalent domain is important in both MSCs and embryonic stem cells. They mentioned that H3K4/H3K9me3 was expressed and inhibited the action of MBDD1/SETDB1/MCAF1 complex. However, once H3K4/H3K9me3 was blocked, the cells differentiated into adipocytes and the signals were activated. In addition, SIRT1 (a class III HDAC) overexpression inhibited adipogenic differentiation in MSCs by deacetylation of the histone promoters sFRP1, sFRP2, and Dact1 and activation of the Wnt signaling pathway.

4. Neurogenic differentiation

In mammals, adult neurogenesis is necessary to regenerate neurons and existing neural circuitry for cognitive functions. Terskikh’s group reported that SOX2-Lin28/let7 complex play an essential role in neuronal stem cell differentiation and proliferation of neural precursor cells. Several studies reported that histone acetylation has a potential effect on neurogenesis in neurodegenerative diseases and CNS injuries.29,50 Currently, scientist have revealed the potential effect of neurogenesis in neurodegenerative diseases and various studies have been conducted on this topic. Acetylation of histones is a crucial factor in neurogenic differentiation in hMSCs. During neurogenic differentiation in hMSCs, VPA (HDAC class I, II) improved histone H3 and H4 acetylation and differentiation in hMSCs.51 Jang et al.55-57 demonstrated that transcriptional control in chromatic remodeling and epigenetic modifications is a vital factor in neurogenic differentiation in hMSCs.

5. Others

Voncken’s group reported that polycomb associated H3K27me3 blocked chromatin access of EGR1 in early chondrogenic epigenetic programming by early gene-environment interactions in chondrogenesis of MSCs. These results suggested that epigenomic remodeling is important in chondrogenesis and depends on the early or late stage during differentiation.

Rogiers’s group reported that hepaticogenic factors combining TSA could show hepatic differentiation of hMSCs following TSA-induced histone acetylation and inducible cytochrome P450-dependent activity.58 TSA is known as one of the HDAC class I, II, IV, and has the potential for cell fate determination during hepatic trans-differentiation in hMSCs.59 A few years ago, Raut and Khanna60 studied the role of microRNAs in the control of cell fate determination during hepatic trans-differentiation in hMSCs. During hepatic differentiation, VPA improved hepatic trans-differentiation by enhancing the expression of heptocyte-specific miRNAs and activation of histone H3 and H4.

There still remains a limitation in the understanding of hair follicle formation and hair genesis in the clinical field. Recently, Guo et al.61 studied how hair follicles rely on dermis MSCs or are regenerated from skin-derived precursors using spheroid. They found TSA-mediated histone H3 acetylation in K9 and K14 modulated a wide variety of cellular activities and markedly alleviated culture expansion and restored the hair inductive capacity.

CONCLUSION

Recent advances in the field of regenerative medicine, Biochemistry, and Molecular Biology have demonstrated that histone modifications in mesenchymal stem cells play crucial roles in determining stem cell fate, including proliferation and differentiation. In this review, we described that histone acetylation followed by HDAC inhibitors or HATs are involved in MSCs differentiation into specialized cell types. This suggests how epigenetic modifications are a promising technique for stem cell therapy and regenerative medicine. Future investigations are needed to identify the link between histone acetylation and stem cell engineering.

ACKNOWLEDGEMENTS

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020 R1F1A1076616, 2020R111A3070388, 2021R111A306043 511), the Chonnam National University Hospital Biomedical Research Institute [BCR121039], and a grant from the Jeollanam-do Science and Technology R&D Project (Development of stem cell-derived new drug) funded by the Jeollanam-do, Korea.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, et al. The structural basis of protein acetylation by the p300/ CBP transcriptional coactivator. Nature 2008;451:846-50.
2. Campbell MJ, Turner BM. Altered histone modifications in cancer. Adv Exp Med Biol 2013;754:81-107.
3. Allfrey VG, Faulkner R, Mirsky RE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A 1964;51:786-94.
4. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 2007;26:5528-40.
5. Farhut MR. Hat1: the emerging cellular roles of a type B histone acetyltransferase. Oncogene 2007;26:5319-28.
6. Podobińska M, Szabolcska-Gadomska I, Augustyniak J, Sandvig I, Sandvig A, Buzanska L. Epigenetic modulation of stem cells in neurodevelopment: the role of methylation and acetylation. Front
24. Lu DF, Yao Y, Su ZZ, Zeng ZH, Xing XW, He ZY, et al. Downregulation of HDAC1 is involved in the cardiomyocyte differentiation of mesenchymal stem cells in a myocardial microenvironment. PLoS One 2014;9:e93222.

25. Yi Q, Xu H, Yang K, Wang Y, Tan B, Tian J, et al. Islet-1 induces the differentiation of mesenchymal stem cells into cardiomyocyte-like cells through the regulation of Gcn5 and DNMT-1. Mol Med Rep 2017;15:2511-20.

26. Xu H, Zhou Q, Yi Q, Tan B, Tian J, Chen X, et al. Islet-1 synergizes with Gcn5 to promote MSC differentiation into cardiomyocytes. Sci Rep 2020;10:1817.

27. Yin N, Lu R, Liu J, Zhi S, Tian J, Zhu J. Islet-1 promotes the cardiac-specific differentiation of mesenchymal stem cells through the regulation of histone acetylation. Int J Mol Med 2014;33:1075-82.

28. Xu H, Yi Q, Yang C, Wang Y, Tian J, Zhu J. Histone modifications interact with DNA methylation at the GATA4 promoter during differentiation of mesenchymal stem cells into cardiomyocyte-like cells. Cell Prolif 2016;49:315-29.

29. Li Z, Liu C, Xie Z, Song P, Zhao RC, Guo L, et al. Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLoS One 2011;6:e20526.

30. Shakibaee M, Shayyan P, Busch F, Aldinger C, Buhrmann C, Luerss C, et al. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One 2012;7:e35712.

31. Wang J, Wang CD, Zhang N, Tong WX, Zhang YF, Shan SZ, et al. Mechanical stimulation orchestrates the osteogenic differentiation of human bone marrow stromal cells by regulating HDAC1. Cell Death Dis 2016;7:e2221.

32. Fu Y, Zhang P, Ge J, Cheng J, Dong W, Yuan H, et al. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity. Int J Biochem Cell Biol 2014;54:68-77.

33. Zhang YX, Sun HL, Liang H, Li K, Fan QM, Zhao QH. Dynamic and distinct histone modifications of osteogenic genes during osteogenic differentiation. J Biochem 2015;158:445-57.

34. Fani N, Ziadlou R, Shahhosseini M, Baghabani Eslaminejad M. Comparative epigenetic influence of autologous versus fetal bovine serum on mesenchymal stem cells through in vitro osteogenic and adipogenic differentiation. Exp Cell Res 2016;344:176-82.

35. Chen D, Wang Z. Adrenaline inhibits osteogenesis via repressing miR-21 expression. Cell Biol Int 2017;41:8-15.

36. Fu L, Peng S, Wu W, Ouyang Y, Tan D, Fu X. LncRNA HOTAIRM1 promotes osteogenesis by controlling JNK/AP-1 signalling-mediated RUNX2 expression. J Cell Mol Med 2019;23:7517-24.

37. Zhang Y, Chen X, Liu Z, Zhang M, Lv L, Zhang X, et al. Histone H3K9 acetyltransferase PCAF is essential for osteogenic differentiation through bone morphogenetic protein signaling and may be involved in osteoporosis. Stem Cells 2016;34:2332-41.

38. Jing H, Su X, Gao B, Shuai Y, Chen J, Deng Z, et al. Epigenetic inhibition of Wnt pathway suppresses osteogenic differentiation of BMSCs during osteoporosis. Cell Death Dis 2018;9:176.

39. Agrawal Singh S, Lerdrup M, Gomes AR, van de Werken HJ, Xu F, Dynamic and distinct histone modifications modulate the expression of key adipogenesis regulatory genes. Cell Cycle 2012;11:4310-22.
41. Sonkar R, Powell CA, Choudhury M. Benzyl butyl phthalate induces epigenetic stress to enhance adipogenesis in mesenchymal stem cells. Mol Cell Endocrinol 2016;431:109-22.

42. Noer A, Lindeman LC, Collins P. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. Stem Cells Dev 2009;18:725-36.

43. Yi SA, Nam KH, Kim S, So HM, Ryoo R, Han JW, et al. Vulpinic acid controls cell fate toward osteogenesis and adipogenesis. Genes (Basel) 2019;11:118.

44. Zhao QH, Wang SG, Liu SX, Li JP, Zhang YX, Sun ZY, et al. PPARγ forms a bridge between DNA methylation and histone acetylation at the C/EBPα gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells. FEBS J 2013;280:5801-14.

45. Liu H, Li J, Lu D, Li J, Liu M, He Y, et al. Ginkgolic acid, a sumoylation inhibitor, promotes adipocyte commitment but suppresses adipocyte terminal differentiation of mouse bone marrow stromal cells. Sci Rep 2018;8:2545.

46. Matsumura Y, Nakaki R, Inagaki T, Yoshida A, Kano Y, Kimura H, et al. H3K4/H3K9me3 bivalent chromatin domains targeted by lineage-specific DNA methylation pauses adipocyte differentiation. Mol Cell 2015;60:584-96.

47. Zhou Y, Song T, Peng J, Zhou Z, Wei H, Zhou R, et al. SIRT1 suppresses adipogenesis by activating Wnt/β-catenin signaling in vivo and in vitro. Oncotarget 2016;7:77707-20.

48. Cimadamore F, Amador-Arjona A, Chen C, Huang CT, Terskikh AV. SOX2-LIN28/let-7 pathway regulates proliferation and neurogenesis in neural precursors. Proc Natl Acad Sci U S A 2013;110:E3017-26.

49. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008;7:854-68.

50. Langley B, Brochier C, Rivieccio MA. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke 2009;40:2899-905.

51. Sheu JR, Hsieh CY, Jayakumar T, Lin GY, Lee HN, Huang SW, et al. HDAC6 dysfunction contributes to impaired maturation of adult neurogenesis in vivo: vital role on functional recovery after ischemic stroke. J Biomed Sci 2019;26:27.

52. Hammond JW, Cai D, Verhey KJ. Tubulin modifications and their cellular functions. Curr Opin Cell Biol 2008;20:71-6.

53. Hammond JW, Huang CF, Kaech S, Jacobson C, Banker G, Verhey KJ. Posttranslational modifications of tubulin and the polarized transport of kinesin-1 in neurons. Mol Biol Cell 2010;21:572-83.

54. Jaworska J, Zalewska T, Sypecka J, Ziemka-Nalecz M. Effect of the HDAC inhibitor, sodium butyrate, on neurogenesis in a rat model of neonatal hypoxia-ischemia: potential mechanism of action. Mol Neurobiol 2019;56:6341-70.

55. Jang S, Jeong HS. Histone deacetylase inhibition-mediated neural differentiation via the Wnt signaling pathway in human adipose tissue-derived mesenchymal stem cells. Neurosci Lett 2018;668:24-30.

56. Jang S, Cho H, Park JS, Jeong HS. Non-canonical Wnt mediated neurogenic differentiation of human bone marrow-derived mesenchymal stem cells. Neurosci Lett 2017;660:68-73.

57. Jang S, Park JS, Jeong HS. Neural differentiation of human adipose tissue-derived stem cells involves activation of the Wnt5a/JNK signalling. Stem Cells Int 2015:2015:178618.

58. Snykers S, Vanhauwe T, De Becker A, Papeleu P, Vinken M, Van Riet I, et al. Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Dev Biol 2007;7:24.

59. Dong X, Pan R, Zhang H, Yang C, Shao J, Xiang L. Modification of histone acetylation facilitates hepatic differentiation of human bone marrow mesenchymal stem cells. PLoS One 2013;8:e63405.

60. Raut A, Khanna A. Enhanced expression of hepatocyte-specific microRNAs in valproic acid mediated hepatic trans-differentiation of human umbilical cord derived mesenchymal stem cells. Exp Cell Res 2016;343:237-47.

61. Guo L, Wang X, Yuan J, Zhu M, Fu X, Xu RH, et al. TSA restores hair follicle-inductive capacity of skin-derived precursors. Sci Rep 2019;9:2867.